Trial Profile
Phase III retrospective trial of telavancin in patients with methicillin-resistant Staphylococcus aureus osteomyelitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2015
Price :
$35
*
At a glance
- Drugs Telavancin (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections; Osteomyelitis
- Focus Adverse reactions; Therapeutic Use
- 14 Oct 2015 New trial record
- 12 Oct 2015 Results presented at IDWeek 2015, according to a Theravance Biopharma media release.
- 12 Oct 2015 Results published in a Theravance Biopharma media release.